Every Form 4 that ZIVO BIOSCIENCE INC (ZIVO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZIVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZIVO filings page.
Zivo Bioscience, Inc. reported that an entity associated with 10% owner Mark E. Strome acquired additional common stock. On April 17, 2026, Strome Mezzanine Fund II, LP purchased 100,000 shares of Zivo common stock at $2.00 per share.
Following this transaction, the reporting group’s indirect holdings rose to 572,942 shares of common stock. The filing notes that the reporting persons may be deemed to share voting and investment power over these shares, while also disclaiming beneficial ownership for certain legal purposes.
Zivo Bioscience director and 10% owner–associated entity buys shares. An entity associated with director and ten percent owner Laith L. Yaldoo, identified as HEP Investment, LLC, made an open-market purchase of 1,543 shares of Zivo Bioscience common stock at $9.72 per share. After this transaction, the filing reports 583,615 shares of common stock indirectly owned.
Zivo Bioscience reported that investment entities associated with 10% owner Mark E. Strome, through Strome Mezzanine Fund II, LP, bought 20,000 shares of common stock at $9.77 per share and 2,000 common stock purchase warrants on February 12, 2026.
After these indirect purchases, the entities reported beneficial ownership of 472,942 common shares and 45,071 warrants.
Zivo Bioscience insider reporting shows an indirect open-market purchase of common stock tied to director and 10% owner Laith L. Yaldoo. On 02/10/2026, HEP Investments LLC, an entity associated with Yaldoo, bought 2,434 shares of Zivo Bioscience common stock at $10.27 per share. Following this transaction, HEP Investments LLC indirectly held 582,072 shares of common stock.
Zivo Bioscience director Alison Cornell reported buying additional company stock. On January 26, 2026, she purchased 11,709 shares of common stock at a price of $8.54 per share. Following this transaction, she directly beneficially owns 279,481 shares of Zivo Bioscience common stock.
Zivo Bioscience, Inc. President and CEO John B. Payne reported an open-market purchase of company stock. On 01/26/2026, he bought 11,709 shares of common stock at $8.54 per share. Following this transaction, he directly owns 19,618 shares of Zivo Bioscience common stock.
Zivo Bioscience director and 10% owner Christopher D. Maggiore reported a small open-market purchase of common stock. On 01/14/2026, he bought 1,766 shares of Zivo Bioscience common stock at a price of $8.49 per share, coded as a purchase transaction.
Following this trade, Maggiore beneficially owned 519,292 shares of Zivo Bioscience common stock in direct ownership form, indicating his stake as both a director and a more than 10% shareholder.
Zivo Bioscience director and 10% owner–associated entity acquires additional shares. On January 14, 2026, an entity associated with Laith L. Yaldoo, HEP Investments LLC, purchased 1,766 shares of Zivo Bioscience common stock at $8.49 per share in an open-market transaction.
Following this purchase, HEP Investments LLC indirectly holds 579,638 shares of Zivo Bioscience common stock attributed to Yaldoo’s beneficial ownership.
Zivo Bioscience, Inc. director and 10% owner reported buying additional company shares. On 11/28/2025, an indirect account, HEP Investments LLC, purchased 2,777 shares of Zivo Bioscience common stock at a price of $9 per share. After this transaction, the reporting person beneficially owned 577,872 shares of common stock indirectly through HEP Investments LLC.